... Presentation Will be Webcast Live and Archived on Company's Websit...ROCKVILLE Md. May 22 /- Vanda Pharmaceuticals...The presentation will take place as part of the FBR Capital Markets12...To access the presentation log on to A HREF http://www.vandapharma....

ROCKVILLE, Md., May 22 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals
Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development
and commercialization of clinical-stage product candidates for central
nervous system disorders, today announced that Mihael H. Polymeropoulos,
M.D., Vanda President and CEO will deliver a corporate presentation on
Wednesday, May 28, 2008, at 9:00 a.m. Eastern Time.

The presentation will take place as part of the FBR Capital Markets
12th Annual Spring Investor Conference at the Grand Hyatt, New York, New
York. Dr. Polymeropoulos' remarks will be available live on the Vanda
Website, where it also will be archived for 30 days.

To access the presentation, log on to http://www.vandapharma.com and
click on the Presentations option in the Investor Relations section. Please
connect to the website several minutes prior to the start of the live
presentation.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is a biopharmaceutical
company focused on the development and commercialization of clinical-stage
product candidates for central nervous system disorders. The company has
three product candidates. Vanda's lead product candidate, Fanapta(TM)
(iloperidone), for which Vanda has recently submitted an NDA to the FDA, is
a compound for the treatment of schizophrenia. Vanda's second product
candidate, tasimelteon (VEC-162), is a compound for the treatment of sleep
and mood disorders, which is currently in Phase III for chronic primary
insomnia. Vanda's third product candidate, VSF-173, is a compound for the
treatment of excessive sleepiness in Phase II. For more on Vanda
Pharmaceuticals Inc., please visit http://www.vandapharma.com.

(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... The next ... now being accepted. , Students who successfully complete the seven-week long Patient Care ... Nurse Assistant (CNA). The average starting salary for a CNA in Kalamazoo is $24,428.* ...

(Date:8/16/2017)... ... 2017 , ... Greenfield Advisors is honored to be named to Inc. Magazine’s ... in a row. The Inc. 5000 list honors private businesses across the country that ... list once is a great accomplishment, but for us to be included again goes ...

(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test ... The company ranked #4429 on the newly released, 36th annual Inc. 5000 , ... unique look at the most successful companies within the American economy’s most dynamic segment ...

(Date:8/16/2017)... New York (PRWEB) , ... August 16, 2017 , ... ... could minimize its appearance with diet and exercise. In fact, cellulite can't always be ... a safer and more effective treatment available to select physicians nationwide. Dr. Kenneth Rothaus ...

(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...

(Date:8/4/2017)... , Aug. 3, 2017 Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131. This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...